**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

| | | | |
|---|---|---|---|
| **Applicants:** | Stanley F. Barnett, et al. | | |
| **Serial No.:** | to be assigned | Case No.: 21062Y | **Art Unit:** to be assigned |
| **Filed:** | October 3, 2003 | | |
| **For:** | COMBINATION THERAPY | | **Examiner:** to be assigned |

Assistant Commissioner for Patents
Washington, D.C. 20231

**COMMUNICATION**

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide and/or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21062Y.

Respectfully submitted,

By: _____
Matthew A. Leff
Registration No. 50,149
Agent for Applicants

Merck & Co., Inc.
P.O. Box 2000 - RY 60-30
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-1404

Date: October 3, 2003

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 10/3/03
EXPRESS MAIL NO. EV321986437US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL POST OFFICE TO ADDRESSEE ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER OF PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY _____
DATE Oct 3, 2003